MAPT and Alzheimer disease: Among these, 18F-flortaucipir (TauvidTM, Avid Radiopharmaceuticals) became the first to be approved by the United States Food and Drug Administration to estimate the density and distribution of aggregated tau NFTs in adult patients with cognitive impairment being evaluated for AD.